9 Meters Biopharma Inc. (NASDAQ:NMTR) has a beta value of -3.9 and has seen 1,906,390 shares traded in the last trading session. The company, currently valued at $305.7 Million, closed the last trade at $1.22 per share which meant it gained $0.01 on the day or 0.83% during that session. The NMTR stock price is -85.25% off its 52-week high price of $2.26 and 64.75% above the 52-week low of $0.43. If we look at the company’s 10-day average daily trading volume, we find that it stood at 13.45 Million shares traded. The 3-month trading volume is 11.17 Million shares.
The consensus among analysts is that 9 Meters Biopharma Inc. (NMTR) is a Buy stock at the moment, with a recommendation rating of 1.6. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 4 have rated it as a Hold, with 4 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.03.
9 Meters Biopharma Inc. (NASDAQ:NMTR) trade information
Sporting 0.83% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Wednesday, Apr 28 when the NMTR stock price touched $1.2575 or saw a rise of 2.98%. Year-to-date, 9 Meters Biopharma Inc. shares have moved 42.03%, while the 5-day performance has seen it change 5.17%. Over the past 30 days, the shares of 9 Meters Biopharma Inc. (NASDAQ:NMTR) have changed -10.29%. Short interest in the company has seen 4.4 Million shares shorted with days to cover at 0.39.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could jump 309.84% from current levels. The projected low price target is $3 while the price target rests at a high of $6. In that case, then, we find that the current price level is +391.8% off the targeted high while a plunge would see the stock lose 145.9% from current levels.
9 Meters Biopharma Inc. (NMTR) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +44.3% over the past 5 years. Earnings growth for 2021 is a modest +28.3%.
9 Meters Biopharma Inc. (NASDAQ:NMTR)’s Major holders
Insiders own 10.79% of the company shares, while shares held by institutions stand at 26.42% with a share float percentage of 29.61%. Investors are also buoyed by the number of investors in a company, with 9 Meters Biopharma Inc. having a total of 61 institutions that hold shares in the company. The top two institutional holders are Orbimed Advisors LLC. with over 25.72 Million shares worth more than $22.09 Million. As of December 30, 2020, Orbimed Advisors LLC. held 11.9% of shares outstanding.
The other major institutional holder is Adage Capital Partners GP L.L.C., with the holding of over 13Million shares as of December 30, 2020. The firm’s total holdings are worth over $11.17 Million and represent 6.02% of shares outstanding.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of December 30, 2020, the former fund manager holds about 2.19% shares in the company for having 4740175 shares of worth $4.07 Million while later fund manager owns 2.06 Million shares of worth $1.77 Million as of December 30, 2020, which makes it owner of about 0.95% of company’s outstanding stock.